135326-22-6

Basic information

• Product Name: GADOXETATE DISODIUM
• Synonyms: GADOXETATE DISODIUM;gadoliniuM coMplex;Gadoxetate;ZK 139834;3Gadoxetate disodium
• CAS NO: 135326-22-6
• Molecular Formula: C23H28GdN3Na2O11
• Molecular Weight: 725.71146
• Mol File: 135326-22-6.mol
• Article Data: 1

Chemical Properties

• Appearance: /
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• CAS DataBase Reference: GADOXETATE DISODIUM(CAS DataBase Reference)
• NIST Chemistry Reference: GADOXETATE DISODIUM(135326-22-6)
• EPA Substance Registry System: GADOXETATE DISODIUM(135326-22-6)

Safety Data

• Hazardous Substances Data: 135326-22-6(Hazardous Substances Data)

Usage

Uses

Paramagnetic contrast agent for enhancement in magnetic resonance imaging (MRI).

Upstream product

• 1310-73-2 sodium hydroxide 

Related news

Evaluation of cystic duct patency: comparison of functional MR cholangiography with GADOXETATE DISODIUM (cas 135326-22-6) and hepatobiliary scintigraphy in suspected acute cholecystitis08/16/2019

PurposeThis study aims to compare assessment of cystic duct patency between gadoxetate disodium MRI and hepatobiliary scintigraphy.detailed

Abdominal vasculature in dynamic contrast-enhanced liver MRI at 3.0 T: an intraindividual comparative study using GADOXETATE DISODIUM (cas 135326-22-6) and gadofosveset trisodium08/15/2019

ObjectivesTo intraindividually compare gadoxetate disodium and gadofosveset trisodium regarding vessel contrast, image quality and vessel delineation in dynamic contrast-enhanced liver MRI at 3.0 T.detailed

GADOXETATE DISODIUM (cas 135326-22-6) enhanced spectral dual-energy CT for evaluation of cholangiocarcinoma: Preliminary data08/12/2019

PurposeEvaluate Gadoxetate Disodium enhanced dual-energy CT for visualization of perihilar cholangiocarcinoma by exploiting the hepatobiliary uptake of Gadoxetate Disodium and viewing images at the k-edge of gadolinium on the spectrum of simulated monoenergetic energies available with Dual Energ...detailed

Preliminary experience with intravenous GADOXETATE DISODIUM (cas 135326-22-6) as a craniospinal MR contrast agent08/10/2019

IntroductionGadoxetate disodium is a gadolinium-based contrast agent (GBCA) typically used for body imaging, as about 50% of its excretion is via the liver. Its use for craniospinal MRI has not been reported.detailed

Relevant articles and documents

Synthesis and physicochemical characterization of a new gadolinium chelate: The liver-specific magnetic resonance imaging contrast agent Gd-EOB-DTPA

A convenient synthesis of disodium ,S-[4-(4-ethoxybenzyl)-3,6,9-tris[(carboxy-κO)methyl]-3,6,9- triazaundecandioato)(5-)-k3,N3N6N 9,k2O1,O11]gadolinate(2-) (Gd-EOB-DTPA), 1, is reported. This water-soluble complex is presently undergoing phase III clinical trials as a liver-specific contrast agent for magnetic resonance imaging (MRI). The thermodynamic complex stability constant of 1 and the acid dissociation constants of the ligand have been determined as well as the stability constant of the calcium complex Ca-EOB-DTPA (2), which is used as an additive in the pharmaceutical formulation of the contrast agent. The solid-state structure of the ligand S-4-(4-ethoxybenzyl)-3,6,9-tris(carboxylatomethyl)-3,6,9-triazaundecanedioic acid (H5EOB-DTPA), 3, has been elucidated in a single crystal X-ray diffraction study. Additionally, HPLC evidence is given that the enantiomerically pure ligand forms two diastereomeric gadolinium complexes in a 65:35 ratio. The kinetics of isomerization of the isolated diastereomers-as dependent on pH and temperature-has been investigated, and thus, the activation energy for the interconversion of these isomers has been estimated to be 75.3 kJ mol-1. Finally, the structures of the two components of 1 are discussed in terms of four possible diastereomers.